spleen, serosal effusions, mucosal ulceration, elevated liver enzymes and hemorrhage. The clinical course is often fatal, 4-6 and liver failure, hemorrhagic diathesis, or infec-A 20-year-old Japanese man developed generalized, subcutaneous, painless nodules, fever, abnormal liver tion are the main causes of death, 2,7,8 but a number of patients with CHP with a benign clinical course have also function, serosal effusions, hepatosplenomegaly, lymphadenopathy and anemia. Skin biopsies revealed lobubeen described. 9 Thus, CHP can have a broad spectrum from mild to severe. In CHP, the following clinical and lar panniculitis with a morphologically benign histiocytic infiltration and prominent phagocytosis. Atypical laboratory features are associated with a poor prognosis: bleeding, mucosal ulcers, lymphadenopathy, fever, hepato-T lymphocytes were also present in the skin and liver. The diagnosis given was aggressive cytophagic histiosplenomegaly, serosal effusions, anemia, leukopenia, elevated liver enzyme levels, coagulopathy and hypercalcemia.
cytic panniculitis (CHP) or aggressive subcutaneous panniculitic T cell lymphoma (SPTCL). He received
Despite the absence of malignant changes within the histiocytic infiltrate, some patients die with hemorrhage and pancyclophosphamide, doxorubicin, and vincristine on day 1, prednisolone on days 1-5, and etoposide on days 1, cytopenia after a variable course. Other workers have suggested that cutaneous hemophagocytosis is observed as a 3 and 5 (CHOP-E), with the support of granulocyte colony-stimulating factor. This regimen was repeated reaction to subcutaneous T cell lymphoma, [10] [11] [12] and this lymphoma has been renamed subcutaneous panniculitic T every 2 weeks and complete clinical remission (CCR) was attained after three cycles of CHOP-E. As the clinicell lymphoma (SPTCL) in the recently proposed revised European-American classification of lymphoid neoplasms cal course of aggressive CHP is recurrent and often fatal, he was given high-dose chemotherapy followed by (REAL classification). 13 An effective therapeutic strategy for aggressive CHP or aggressive SPTCL has not been autologous peripheral blood stem cell transplantation (APBSCT), after five cycles of CHOP-E. He has established. We describe here the clinical features in a young man with aggressive CHP and our successful treatremained in CCR for 12 months after APBSCT. Highdose chemotherapy followed by APBSCT is considered ment which included APBSCT. to be one of the most beneficial therapies for patients with aggressive CHP and aggressive phase SPTCL. Keywords: cytophagic histiocytic panniculitis (CHP);
Case report CHOP-E; APBSCT In 1990, a 15-year-old Japanese man developed small nontender subcutaneous nodules on his left cheek which disappeared spontaneously within a few weeks, leaving only a Cytophagic histiocytic panniculitis (CHP), a disorder few depressions. Skin biopsy of the lesions demonstrated described by Winkelmann et al 1 and Crotty et al, 2 is characatypical lymphocytes infiltrating to subcutaneous fatty terized by lobular panniculitis and infiltration with histotissue. He was suspected of having subcutaneous lymlogically benign histiocytes showing erythrophagocytosis phoma, but was lost to follow-up. In September 1995, he and lymphophagocytosis. The major clinical features are developed a painless subcutaneous nodule on his left cheek. recurrent fever, multiple panniculitic lesion, anemia, leukoOne month later, he had intermittent fever, and noted penia and coagulation abnormalities. 3 In the later phases of additional nodules on his extremities and trunk. The size this disease, there may be involvement of the liver and of the nodule on his left cheek gradually enlarged. On admission to the Hospital of Hokkaido University School of Medicine in November 1995, he was febrile and the vital ascites, massive hepatosplenomegaly, and lymphadenopasubcutaneously, was administered, as described elsewhere; 14 this made it feasible to administer CHOP-E every thy of the aorta abdominalis. Blood examination showed a hemoglobin of 9.4 g/dl, a white cell count of 5.1 × 10 9 /l, 2 weeks. He tolerated the CHOP-E well and all signs and symptoms of CHP completely disappeared after three with 94% neutrophils, 4% lymphocytes and 2% monocytes, and a platelet count of 124 × 10 9 /l. The prothrombin time cycles to January 1996. Physical examination and accessory clinical laboratory tests, including a complete blood count was shortened to 10.2 s, activated partial thromboplastin time was prolonged to 42.7 s, fibrinogen was 261 mg/dl, and automated chemistries also reverted to normal. After the fourth course of CHOP-E, he underwent leukaphereis fibrinogen degenerative products were increased to 20.7 g/ml, and d-dimer was increased to 8.81 g/ml.
twice, using the mobilization treatment of G-CSF as described elsewhere. 15 After the fifth cycle of CHOP-E, Liver function values were increased: SGOT 239 IU/l, SGPT 206 IU/l, LDH 1696 IU/l, ␥-GTP 186 IU/l, ALP APBSCT was given. The conditioning regimen before APBSCT consisted of 200 mg/m 2 ranimustine (MCNU) on 1637 IU/l, and total bilirubin 0.5 mg/dl. The total serum protein was 6.2 g/dl, and albumin decreased to 2.6 g/dl. His days −8 and −3, 300 mg/m 2 carboplatin (CBDCA) on days −7 to −4, 500 mg/m 2 etoposite (VP-16) on days −6 to −4, total cholesterol was 93 mg/dl and triglycerides 184 mg/dl. Tests for antinuclear antibody (ANA) and rheumatoid facand 50 mg/kg cyclophosphamide on days −3 and −2 (MCVC regimen). This conditioning regimen commenced tor gave negative results. Serum Fe was 31 g/dl, TIBC 98 g/dl, UIBC 67 g/dl, and ferritin was markedly elevon 3 March 1996, and PBSC were re-infused on day 0. The number of cells infused was 7.39 × 10 6 /kg CD34 + cells and ated to 2017 ng/ml. Serological tests for Epstein-Barr virus (EBV)-related antibodies gave the following: titers of IgG 10.2 × 10 5 /kg CFU-GM. After PBSCT, the time required to recover neutrophils to over 0.5 × 10 9 /l and platelets to over antibody to viral capside antigen (VCA) 1:320, IgM-VCA less than 1:10, IgA-VCA 1:10, EB nuclear antigen (EBNA) 50 × 10 9 /l was 8 and 11 days, respectively. During the period of neutropenia and thrombocytopenia, pyrexia and nasal 1:320 and IgG early antigen less than 1:10. The antibody to human immunodeficiency virus (HIV) and human T lymhemorrhage occurred. Both subsided with antibiotics and platelet transfusions and hematologic recovery. He was disphocytotropic virus-1 (HTLV-1) was negative, antibody to hepatitis C negative, and antigen and antibody to hepatitis charged at the end of March 1996, and remains in complete remission 12 months after PBSCT. Maintenance chemo-B were negative. Bone marrow biopsy showed a hypercellular marrow with relative granulocyte, monocyte and therapy has not been given. histiocyte hyperplasia, but with no evidence of infiltration by lymphoma cells or hemophagocytes.
An elliptical biopsy was taken of the nodule on the left Discussion cheek. The epidermis was unremarkable with the papillary dermis showing minimal perivascular mononuclear cell Our patient had clinical features indicative of a poor prognosis: fever, hepatosplenomegaly, lymphadenopathy, seroinfiltration. Striking histopathologic changes were found in the subcutaneous fatty tissue which was atrophic and edemsal effusions, anemia, coagulopathy and elevated liver enzyme levels. Biopsy of the subcutaneous mass and the atous, with an acute inflammatory infiltration of neutrophils, eosinophils, atypical lymphocytes and histiocytes.
liver showed an infiltration with atypical T lymphocytes, suggesting that subcutaneous panniculitic T cell lymphoma Some histiocytes, occasional phagocytosed white blood cells, red cells and cell particles were also present. These (SPTCL) in the REAL classification underlaid the features of CHP. Primary T cell lymphoma has been identified in hemophagocytic histiocytes produced a 'bean bag' appearance. The histiocytes appeared benign and had normal some patients with CHP, when symptoms often overlap with those of malignant histiocytosis. 8,11,16,17 Gonzalez et nuclei without heterochromatin, and normal nuclear-cytoplasmic ratios. Immunohistochemical studies showed that al 17 described eight cases of T cell lymphoma involving subcutaneous tissue. The tumors were histologically the atypical lymphocytes were positive for CD45RO, LCA, CD3 and negative for CD20, MT-1, MB-1, which predomiaggressive and were associated with a hemophagocytic syndrome which was a common cause of death in these cases. nantly shows a T cell profile. Histiocytes revealed positive cytoplasmic reactivity with ␣ 1 -antitrypsin and KP-1.
Based on their literature review, Gonzalez and colleagues concluded that previous reports of cutaneous malignant hisResults of a liver biopsy specimen showed an intact architecture with minor infiltration of atypical lymphoid cells in tiocytosis and histiocytic cytophagic panniculitis probably also included cases of T cell lymphoma involving subcutthe portal tract. The clinical and histologic findings led to diagnosis of CHP or SPTCL in the REAL classification.
aneous tissue. These tumors have since been incorporated as a provisional entity in the recently proposed revised EurOn the 17th hospital day, prednisolone, 50 mg/m 2 daily, was started. Although febrile episodes soon subsided, the opean-American classification of lymphoid neoplasms, and renamed SPTCL. 13 The lymphoma may behave indolently other symptoms remained. We therefore initiated combination chemotherapy, consisting of cyclophosphamide for months to years, but in most instances it enters an acute, aggressive phase in which the majority of patients 750 mg/m 2 on day 1 (i.v.), doxorubicin 50 mg/m 2 on day 1, vincristine 1.4 mg/m 2 (2 mg/body as a maximum dose) developed a fatal hemophagocytic syndrome. 18 Twelve cases of subcutaneous T cell lymphoma which developed on day 1, prednisolone 50 mg/m 2 on day 1-5 (i.v.) and etoposide 100 mg/m 2 on day 1, 3 and 5 (i.v.) (CHOP-E into a fatal hemophagocytic syndrome have been described in the literature to date. 7, 11, [16] [17] [18] [19] [20] Outcome was fatal, with no regimen) on 9 December 1995. While neutropenia was present, recombinant human granulocyte colony-stimulatremission in the majority (11/12 cases) despite aggressive treatment with chemotherapy and radiotherapy. In partiing factor (G-CSF: lenograstim) at a dose of 2 g/kg/day, It is difficult to assess the necessity for high-dose chemoclassification of lymphoid neoplasms: a proposal from the therapy followed by APBSCT, and to predict the eventual 
